Ultivue

Ultivue provides advanced multiplexed tissue biomarker assays using its proprietary InSituPlex® technology. These enable high-throughput spatial profiling of tissues with AI-driven image analysis to support precision oncology research. Their solutions are widely adopted by researchers developing personalized cancer therapies but do not themselves constitute therapeutics or drugs. No clinical trial results as the company does not develop drugs directly. Products include pre-configured panels for key immune-oncology markers such as PD‑L1, PD‑1, T-cell activation markers; custom assay development services; and cloud-based AI analytics platforms. The company’s technologies have been validated in translational studies supporting drug development pipelines at biopharma partners.